Recurrent or Refractory Disease After Standard Therapies Clinical Trials in Shenzhen, Guangdong
2 recruitingShenzhen, Guangdong, China
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
Primary Peritoneal CarcinomaFallopian Tube CarcinomaEpithelial Ovarian Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07617753
Recruiting
Phase 1Phase 2
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Primary Peritoneal CarcinomaFallopian Tube CarcinomaEpithelial Ovarian Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07480954